Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Sarah Godfrey
  • Sarah Godfrey

JPMorgan Claverhouse - Raising dividends for more than half a century

While it may not share the long history of some of its peers at the top of the AIC's list of dividend heroes (at just over 60 years since incorporation, versus 120-plus for City of London IT), JPMorgan Claverhouse's 52-year record of consecutive annual dividend growth is both impressive and unlikely to be put in jeopardy, making the trust a solid option for investors in search of a dependable stream of dividends. The management team's blend of faster- growth stocks alongside those with higher yi...

Sarah Godfrey
  • Sarah Godfrey

CT UK High Income Trust - Management change revitalises performance

Although its corporate structure may be unusual, with ordinary and B shares aimed at investors with different tax positions, CT UK High Income Trust (CHI) is managed without bells and whistles, seeking to achieve income and capital growth from a sensibly constructed portfolio of predominantly UK equities chosen from across the market capitalisation spectrum, augmented by a modest level of gearing. Manager David Moss has a wealth of experience built through more than 25 years at the same firm, an...

Sarah Godfrey
  • Sarah Godfrey

Schroder UK Mid Cap Fund - The only trust for dedicated FTSE 250 expos...

Following the merger of J.P. Morgan's UK mid- and small-cap trusts into a single entity, Schroder UK Mid Cap Fund is now the only dedicated UK mid-cap investment trust. Not only is the mid-cap space a deep pool of innovative and entrepreneurial companies both domestically and internationally focused; the FTSE 250 index has also produced as many '21-baggers' (stocks with a return of 21x or more) as the US in the 21 years to November 2024, as well as surpassing the S&P 500 index return over 25 yea...

Colin Smith
  • Colin Smith

TheraCryf (TCF) | Pharmaron contracted to progress Ox-1 programme

Following its £4.25m fund raise last February, TheraCryf has now appointed Pharmaron, a leading contract manufacturing and research organisation (CMD/CRO), to progress development of TheraCryf's Orexin programme for the treatment of addiction to the point at which clinical trials in humans can commence. Pharmaron is expected to commence work imminently with expected completion of all necessary studies in 2H26 leaving TheraCryf on track to start a Phase 1 clinical trial in 2026, subject to fundin...

Colin Smith
  • Colin Smith

Polarean Imaging | FY24 results – sales growth guidance reiterated

Polarean has more than tripled revenue YoY to US$3.1m for the year to December 2024 and raised the gross margin by 841 basis points, confirming that it is on a path to hyperbolic growth. Almost more importantly, the cost of a Phase III trial for the use of its XENOVIEW® technology in gas exchange has been halved to US$4.0m-US$4.5m. The cash runway has been extended to 2Q26 and the company reiterated revenue guidance for 2025 of US$5.0m-US$6.0m. Polarean has potential upside many times its curren...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch